Improvement of Animal Models and Development Technologies for Stem Cell-Based Regenerative Medicine (STTR)(R41/R42)
|Incentive Type:||Grant Program|
Medical, Research, Health And Safety
|Governing Body:||National Institutes of Health|
|What’s it worth?:||Not mentioned|
The Improvement of Animal Models and Development of Technologies for Stem Cell-Based Regenerative Medicine program funds research activities focused on improving existing or creating new animal models for regenerative medicine applications. Priority will be giving to the following types of projects:
- Development of genetic, phenotypic and epigenetic characterization of animal stem cells.
- Development and characterization of stable, well characterized pluripotent large animal species stem cells.
- Improving testing methods of efficacy and potency of MSCs in animals.
- Development of new techniques for
– Non-invasive guiding and verifying cell injection
– Tracking cell migration
– Monitoring long-term integration
– Survival of grafted stem cells
- Development of approaches that increase grafted cells retention and survival.
- Development of technologies to increase mammalian stem cell reprograming.
- Development of rigorous evaluation and resolution approaches associated with stem cell therapy.
- Develop new methods and animal models to evaluate animal and human stem cell-derived progenitor and differentiated cell transplantation safety.
- Development of animal models for human disease conditions.
Typical award amounts of not more than $225,000 for Phase I projects and up to $1,500,000 for Phase II projects with project duration of up to two years. All applicants must meet the following criteria.
This program does not have any cost sharing requirements. Applications must be complete and received before the deadline.